» Articles » PMID: 40002561

Transcriptome Study in Sicilian Patients with Huntington's Disease

Abstract

: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the expansion of the CAG nucleotide repeat in the first exon of the huntingtin () gene. The disease typically manifests between the second and third decades of life and progresses gradually. The pathogenesis of HD involves the dysregulation of gene expression, influenced by various molecular processes ranging from transcription to protein stability. : To investigate potential variations in gene expression associated with HD, a transcriptome study was conducted using peripheral blood mononuclear cell samples from 15 HD patients and 15 controls, all of Sicilian origin. : The analysis identified 7179 statistically significant differentially expressed genes between the two groups. Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GO) terms were applied to identify the pathways affected by these differentially expressed mRNAs. The GSEA results highlighted significant associations between HD and GO pathways related to ribosomal functions and structure. These pathways were predominantly characterized by negative expression, with a substantial number of genes showing dysregulation. This suggests that the molecular processes leading to protein translation via ribosomes may be impaired in HD. Furthermore, dysregulation was observed in genes and non-coding RNAs involved in regulatory roles across various transcriptional processes. : These findings support the hypothesis that the entire process, from transcription to translation, is disrupted in HD patients carrying the CAG repeat expansion in the first exon of the gene.

References
1.
Lee J, Hwang Y, Ryu H, Kowall N, Ryu H . Nucleolar dysfunction in Huntington's disease. Biochim Biophys Acta. 2013; 1842(6):785-90. PMC: 3972370. DOI: 10.1016/j.bbadis.2013.09.017. View

2.
Tsoi H, Chan H . Expression of expanded CAG transcripts triggers nucleolar stress in Huntington's disease. Cerebellum. 2013; 12(3):310-2. DOI: 10.1007/s12311-012-0447-6. View

3.
Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

4.
Boudreau R, McBride J, Martins I, Shen S, Xing Y, Carter B . Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009; 17(6):1053-63. PMC: 2835182. DOI: 10.1038/mt.2009.17. View

5.
Lee H, Fenster R, Pineda S, Gibbs W, Mohammadi S, Davila-Velderrain J . Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation. Neuron. 2020; 107(5):891-908.e8. PMC: 7486278. DOI: 10.1016/j.neuron.2020.06.021. View